Genome Technology Center


The Stanford Genome Technology Center (SGTC), formerly the Stanford DNA Sequencing and Technology Center, has been funded since 1993 by the National Human Genome Research Institute (NHGRI; and its predecessor) of the U.S.A. National Institutes of Health (NIH). SGTC is headed by Director Ronald W. Davis, PhD, Professor of Biochemistry and Genetics and Co-Director Lars Steinmetz, PhD, Professor of Genetics.

The SGTC was originally funded with two primary missions:

Meeting our goals

The Stanford Genome Technology Center has been successful in developing technologies for biology and medicine.

The SGTC has received numerous patents [1][2]for the instrumentation and the software that we have developed. The instrumentation, robotics, and software that we have invented and/or developed have been transferred from Stanford University to the commercial sector by the Stanford University Office of Technology Licensing. Such instrumentation often carries the SUTECH® logo, which was developed in conjunction with the Stanford University Office of Technology Licensing. As a direct result of these activities, the SGTC is an ongoing major contributor to a whole new industry, that of commercial genomics. Current activities toward the first goal is described in detail on the SGTC Technology Development Group pages. SGTC has spun-off several companies and has numerous ongoing collaborations.

The genome sequence of Saccharomyces cerevisiae S288c was completed by the international collaboration, released to GenBank, and published in 1996. The SGTC contributed 872 kb of fully finished DNA sequence: all of chromosome V, a substantial portion of chromosome IV, and a tiny portion of chromosome XVI. Further information about the Saccharomyces cerevisiae S288c genome can be obtained by accessing the Saccharomyces Genome Database. Since the successful completion of the S. cerevisiae genome sequence, the SGTC has completed, and published, two bacterial genome sequences, those of Chlamydia trachomatis and C. pneumoniae. The SGTC has been a major participant in the international Malaria (Plasmodium falciparum) Genome Project and the Arabidopsis thaliana (model plant) Genome Project. Both of these genome sequences have been published in the journal Nature. We also participated (in a small way) to the Human Genome Project. The diploid genome sequence of Candida albicans has been published in 2004 (PNAS | May 11, 2004 | vol. 101 | no. 19 | 7329-7334) and the genome of the Basidiomycetous Yeast and Human Pathogen Cryptococcus neoformans was published in 2005 (Science 25 February 2005: Vol.307. no.5713, pp.1321-1324).

The success of our efforts has been driven by the ability of the SGTC to attract an interdisciplinary team of physicists, computer scientists, engineers, chemists, and mathematicians to work alongside biologists, biochemists, and physicians for the purpose of employing genomics approaches to attack fundamental problems in biology and medicine. This interdisciplinary approach gives the SGTC a unique ability to identify future technology needs and to develop and implement those technologies.

With NIH-funded large-scale DNA sequencing now consolidated at a few very large centers, we are concentrating on developing new technologies for functional genomics, particularly for complex genomes such as human. In 2000, we changed the name of our center to the SGTC to reflect a shift in our focus.


Footer Links: